Chimerix, Inc. (CMRX)
Largest Insider Buys in Sector
CMRX Stock Price History Chart
CMRX Stock Performance
About Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic …
Insider Activity of Chimerix, Inc.
Over the last 12 months, insiders at Chimerix, Inc. have bought $0 and sold $7,673 worth of Chimerix, Inc. stock.
On average, over the past 5 years, insiders at Chimerix, Inc. have bought $174,564 and sold $7.53M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,295 shares for transaction amount of $16,522 was made by MIDDLETON FRED A (director) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Chimerix, Inc.
| 2024-08-08 | Sale | PRESIDENT AND CEO | 1,285 0.0014% | $0.83 | $1,065 | +7.84% | ||
| 2024-02-14 | Sale | PRESIDENT AND CEO | 1,744 0.0019% | $1.04 | $1,809 | -10.61% | ||
| 2024-02-14 | Sale | VP OF FINANCE AND ACCOUNTING | 2,660 0.003% | $1.04 | $2,777 | -10.61% | ||
| 2024-02-14 | Sale | CHIEF FINANCIAL OFFICER | 1,940 0.0022% | $1.04 | $2,023 | -10.61% | ||
| 2023-11-17 | director | 17,295 0.0192% | $0.96 | $16,522 | -1.34% | |||
| 2023-11-10 | director | 2,705 0.003% | $0.92 | $2,489 | +0.63% | |||
| 2023-09-28 | Sale | VP of Finance and Accounting | 3,610 0.0042% | $0.99 | $3,584 | -1.44% | ||
| 2023-09-25 | director | 20,000 0.0226% | $0.98 | $19,636 | -2.43% | |||
| 2023-05-18 | Chief Business Officer and CFO | 51,700 0.0598% | $1.14 | $59,150 | -10.71% | |||
| 2023-05-12 | Chief Executive Officer | 87,000 0.0987% | $1.12 | $97,652 | -9.82% | |||
| 2023-05-10 | director | 18,000 0.02% | $1.11 | $19,980 | -10.62% | |||
| 2023-05-08 | director | 8,750 0.0101% | $1.14 | $9,975 | -9.82% | |||
| 2023-03-28 | director | 20,000 0.023% | $1.21 | $24,152 | -10.92% | |||
| 2023-01-26 | Sale | Principal Accounting Officer | 3,230 0.0036% | $1.76 | $5,686 | -36.80% | ||
| 2022-09-29 | Sale | Principal Accounting Officer | 4,400 0.005% | $1.86 | $8,185 | -24.86% | ||
| 2022-09-29 | 20,000 0.0229% | $1.86 | $37,176 | -24.86% | ||||
| 2022-05-19 | 1,419 0.0015% | $2.05 | $2,909 | -16.36% | ||||
| 2022-05-19 | 20,000 0.0212% | $2.04 | $40,738 | -16.36% | ||||
| 2022-05-17 | Chief Business Officer and CFO | 15,000 0.0168% | $1.71 | $25,635 | +5.14% | |||
| 2022-05-17 | 10,000 0.0105% | $1.61 | $16,100 | +5.14% |
Insider Historical Profitability
| Andriole Michael T. | PRESIDENT AND CEO | 462453 0.5142% | $3.01 | 4 | 2 | +44.13% |
| MARIO ERNEST | director | 108167 0.1203% | $3.01 | 19 | 9 | +22.4% |
| MIDDLETON FRED A | director | 100000 0.1112% | $3.01 | 12 | 0 | +17.74% |
| Berrey M Michelle | President and CEO | 99685 0.1108% | $3.01 | 5 | 0 | +24.59% |
| Sherman Michael A. | Chief Executive Officer | 87000 0.0967% | $3.01 | 3 | 0 | +23.84% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $9.33M | 9.82 | 8.8M | 0% | +$0 | 0.01 | |
| Monaco Asset Management Sam | $4.64M | 4.88 | 4.38M | 0% | +$0 | 2.13 | |
| The Vanguard Group | $4.61M | 4.85 | 4.35M | 0% | +$0 | <0.0001 | |
| Armistice Capital Llc | $2.4M | 2.53 | 2.26M | -12.86% | -$354,040.00 | 0.01 | |
| Acadian Asset Management | $2.3M | 2.43 | 2.17M | +15.51% | +$309,325.09 | 0.01 |